ARCHIVES

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

Oncotype DX Cancer Test Can Predict Recurrence

November 25, 2011

New Treatment Approaches Valuable For Cancer Pain, Quality Of Life

September 27, 2002

Galeterone Shows Potential In CRPC AR Variants, Study Says

November 28, 2014

CCIRC Disapproves NCOG Renewal, But Carter Plan Appeal To NCAB; Setback For NCI On Regional Groups

March 6, 1981

DCT Board Okays $3 Million In New Programs, $8 Million In Recompetitions

October 24, 1980

UC Davis Becomes 41st Center to Earn NCI Comprehensive Designation

March 16, 2012